Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tralokinumab treatment for patients with moderate-to-severe atopic dermatitis in daily practice
Anne R. Schlösser, Madena Shareef, Jill I. Olydam, et al.
Clinical and Experimental Dermatology (2023) Vol. 48, Iss. 5, pp. 510-517
Open Access | Times Cited: 25

Showing 25 citing articles:

Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors
Richard W. Kim, Megan Lam, Katrina Abuabara, et al.
American Journal of Clinical Dermatology (2024) Vol. 25, Iss. 2, pp. 179-193
Closed Access | Times Cited: 19
Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results
J Rodríguez, Pedro Herranz, Ricardo Ruíz‐Villaverde, et al.
Clinical and Experimental Dermatology (2023) Vol. 48, Iss. 9, pp. 991-997
Closed Access | Times Cited: 22
Effects of Tralokinumab on Clinical and Laboratory Indexes in Atopic Dermatitis: A 24-Week Real-World Study
Teppei Hagino, Marina Onda, Hidehisa Saeki, et al.
Dermatitis (2024)
Closed Access | Times Cited: 8
Efficacy and safety of tralokinumab in the treatment of head and neck pattern atopic dermatitis: A multicentre study of 12 patients
F.J. Navarro‐Triviño, María Salazar‐Nievas, Juan Luís Sanz-Cabanillas, et al.
Australasian Journal of Dermatology (2024) Vol. 65, Iss. 3, pp. 260-265
Closed Access | Times Cited: 5
Effectiveness of Switching From Upadacitinib to Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis: A Real-World Clinical Practice
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Annals of Dermatology (2025) Vol. 37
Open Access
Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis
Amalie Thorsti Møller Rønnstad, Christopher G. Bunick, Raj Chovatiya, et al.
American Journal of Clinical Dermatology (2025)
Closed Access
Long-term Outcomes of New Systemic Agents in Atopic Dermatitis: Drug Survival Analyses and Treatment Patterns in Daily Practice
Anne R. Schlösser, Lars Nijman, Renske Schappin, et al.
Acta Dermato Venereologica (2025) Vol. 105, pp. adv41504-adv41504
Open Access
Predictive Factors for Poor Responders to Tralokinumab in Moderate-to-Severe Atopic Dermatitis: A Real-World Analysis
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Dermatitis (2025)
Closed Access
Effectiveness of Tralokinumab for Different Anatomical Sites and Clinical Signs in Atopic Dermatitis: A 36-Week Real-World Study
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Dermatitis (2025)
Closed Access
Effectiveness and Safety of Tralokinumab in Atopic Dermatitis: 1-year Results From a Real-world Multicentre Study
Laura Marina Calabrese, Élisa Cinotti, Martina D’Onghia, et al.
Acta Dermato Venereologica (2025) Vol. 105, pp. adv42275-adv42275
Open Access
Long-Term Disease Control and Minimal Disease Activity of Head and Neck Atopic Dermatitis in Patients Treated with Tralokinumab up to 4 Years
Raj Chovatiya, Simone Ribero, Andreas Wollenberg, et al.
American Journal of Clinical Dermatology (2025)
Open Access
Recognizing secondary infection in patients with atopic dermatitis: Head & neck atopic dermatitis
О. Б. Тамразова, A. V. Tamrazova, Г. А. Новик, et al.
Meditsinskiy sovet = Medical Council (2025), Iss. 2, pp. 42-48
Open Access
Distinct T cell signatures are associated with Staphylococcus aureus skin infection in pediatric atopic dermatitis
Julianne Clowry, Daniel J Dempsey, Tracey J. Claxton, et al.
JCI Insight (2024) Vol. 9, Iss. 9
Open Access | Times Cited: 3
Effectiveness of dupilumab in tralokinumab‐resistant patients with atopic dermatitis: A real‐world experience from two referral centres
Gianluca Tavoletti, Alessandra Chiei Gallo, Luigi Gargiulo, et al.
Journal of the European Academy of Dermatology and Venereology (2024)
Closed Access | Times Cited: 3
Successful treatment of dyshidrotic palmoplantar eczema with tralokinumab
Nisha V. Parmar, Anwar Al Hammadi
Australasian Journal of Dermatology (2024) Vol. 65, Iss. 6
Closed Access | Times Cited: 2
Interleukin antagonists for atopic dermatitis: a new era of therapy
Aikaterini Tsiogka, Eleni Paschou, Dimitra Koumaki, et al.
Expert Opinion on Investigational Drugs (2024) Vol. 33, Iss. 6, pp. 549-559
Closed Access | Times Cited: 2
Fungal Head and Neck Dermatitis: Current Understanding and Management
Albert C. Chong, F.J. Navarro‐Triviño, Malcolm Su, et al.
Clinical Reviews in Allergy & Immunology (2024) Vol. 66, Iss. 3, pp. 363-375
Open Access | Times Cited: 2
Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects
Miguel Antonio Lasheras‐Pérez, Rodolfo David Palacios‐Diaz, Mónica Pozuelo‐Ruiz, et al.
International Journal of Dermatology (2023) Vol. 63, Iss. 1, pp. 105-107
Closed Access | Times Cited: 4
Atopic dermatitis: real-life experience with tralokinumab after dupilumab failure: a case series
Patrícia Amoedo, Gilberto Pires da Rosa, Teresa Baudrier, et al.
Anais Brasileiros de Dermatologia (2024) Vol. 99, Iss. 5, pp. 721-724
Open Access | Times Cited: 1
Identification of Early and Late Responders to Anti-IL-13 Antibody Tralokinumab in Atopic Dermatitis: A Real-World Japanese Study
Teppei Hagino, Hidehisa Saeki, Eita Fujimoto, et al.
Dermatitis (2024)
Closed Access | Times Cited: 1
ABCs of Biologics in Pediatric Eczema: An Updated Review on the Safety and Efficacy of Systemic Treatments for Pediatric Atopic Dermatitis and Future Directions
Sarah Kamsiah Zemlok, JiaDe Yu
Current Dermatology Reports (2024)
Closed Access
Switching from dupilumab to tralokinumab or Janus kinase inhibitors in cases of ocular and/or facial adverse events in patients with atopic dermatitis: a multicenter retrospective study
Alexandre Beyrouti, Juliette Deuze, Éric Fontas, et al.
The Journal of Allergy and Clinical Immunology In Practice (2024)
Closed Access
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28‐Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels
Coco Dekkers, Nicolaas P. A. Zuithoff, Daphne S. Bakker, et al.
Allergy (2024)
Closed Access
Dermatite atópica: experiência da prática clínica com traloquinumabe após falha com dupilumabe: série de casos
Patrícia Amoedo, Gilberto Pires da Rosa, Teresa Baudrier, et al.
(2024) Vol. 99, Iss. 5, pp. 721-724
Open Access
Association between IL-25, IL-33 and atopic dermatitis: A systematic review and meta-analysis
Boyang Zhou, Xueping Yue, Surong Liang, et al.
European Journal of Inflammation (2023) Vol. 21
Open Access
Page 1

Scroll to top